Combination chemotherapy of S-1 plus biweekly docetaxel for advanced and recurrent gastric cancer

Pharmacology, Toxicology and Pharmaceutical Science

• Docetaxel 100%
• Stomach Cancer 66%
• Combination Therapy 50%
• Chemotherapy 33%
• Antitumor Activity 33%
• Drug 16%
• Incidence 16%
• Adverse Event 16%
• Leukopenia 16%
• Anorexia 16%
• Neutropenia 16%
• Mucosa Inflammation 16%
• Nude Rat 16%